✉news HealthMedicine first seen 5 h ago, last 5 h ago, peak #23

Editas Medicine Stock Sees $5.80 Analyst Price Target

Original: Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to Analysts

Editas Medicine, the NASDAQ-listed gene editing company trading under the ticker EDIT, carries a consensus price target of $5.80 according to analyst coverage aggregated by MarketBeat. The figure reflects the average of Wall Street analyst estimates for the stock. Further detail on individual ratings, upgrades or downgrades was not provided in the report.

Why now: Investors are tracking analyst sentiment on Editas Medicine as a biotech stock with speculative price targets.

Editas MedicineNASDAQMarketBeat

Open on news →

Evidence

• Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to Analysts · MarketBeat

API: https://socialmediatrends-api.osmike.com/v1/trends/1088433